Cellulite is defined as a localized metabolic disorder of subcutaneous tissue.
The main clinical symptom is a modification of the topography of the skin characterized by skin dimpling and nodularity. Diagnosis is based on the clinical features of the disease. At the microscopic level, cellulite presents with herniation of subcutaneous fat with fibrous connective tissue, leading to an orange peel-like or padded appearance of the skin.
The condition occurs mainly in postpubertal women on the pelvic region, lower limbs and the abdomen, and is divided in four stages.
The first stage affects the microcirculation of the skin, with no superficial changes observed.
During the second stage (secretion stage) the vasodilation is converted into the release of liquids to the extracellular space, and the skin starts to develop an orange peel-like texture.
The third stage (fibrosing stage) is characterized by an increase in number and size of adipose cells which form micronodules (cluster). The hypodermal septa thicken and become turgid. The spongy appearance of the skin becomes obvious in a lying position.
The fourth stage (sclerosis stage) can be seen as aggravation of the fibrosing stage, with the hypodermal septa becoming harder and further thickening. The irregularities, depressions and protrusions of the skin are visible to the naked eye.
The etiology of cellulite is multifactorial, with the following factors playing important roles:
- (i) genetic predisposition;
- (ii) gender (females >>males);
- (iii) ethnicity (caucasians >> Asians);
- (iv) lifestyle (an excessive, high-carbohydrate diet results in hyperinsulinemia, promoting lipogenesis; and prolonged periods of sitting and/or standing may cause alterations in the microcirculation of cellulite prone areas); and
- (v) pregnancy.
Additional factors are localized tissue vascularity, hormonal influences, and postinflammatory changes. However, the actual differences between the pathophysiology of cellulite and ‘‘normal’’ fat are largely unknown.
Approximately 85-98% of all postpubertal females display some degree of cellulite, without definite explanation for its presentation. Nevertheless, affected women seem to have fewer and mostly perpendicular hypodermal fibrous septae, whereas unaffected men and women have more of these septae and they are arranged in a "criss-cross" pattern in.
Various treatments for cellulite have been developed, such as (in order of decreasing evidence-based medicine [EbM] level*): laser-assisted lipolysis (EbM level I-A), topical phosphatidylcholine and LED (I-A), endermology (II-A), radiofrequency (II-A), topical herbs and retinol (II-A), ultrasound (II-A), carboxy therapy (II-B), mesotherapy (II-B), weight loss (II-B), liposuction (III), cryolipolysis (IV), and subcision (IV). Radial shock wave therapy (RSWT) has been demonstrated being efficient for cellulite stages II and III (EbM level IIB), with improvement by approximately one stage for several months.
*Level IA: evidence from metaanalysis of randomized controlled trials.
Level IB: evidence from at least one randomized controlled trial.
Level IIA: evidence from at least one controlled study without randomization.
Level IIB: evidence from at least one other type of experimental study.
Level III: evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case control studies
Level IV: evidence from expert committee reports or opinions or clinical experience of respected authorities, or both.
Locate the area of pain through palpation and biofeedback.
Mark the area of pain.
3. APPLY GEL
Apply coupling gel to transmit shock waves to the tissue.
4. APPLY SHOCK WAVES
Deliver Radial or Focused Shock Waves to the area of pain while keeping the applicator firmly in place on the skin.
|Number of treatment sessions||8|
|Interval between two sessions||2 times a week|
|Air pressure Evo Blue®||3 to 4 bar|
|Air pressure Power+||2.5 to 4 bar|
|Impulses||200 - 300 impulses / cm2|
|Frequency||12Hz to 20Hz|
Radial shock wave therapy to treat cellulite, abstract ATRAD World Congress 2010, p.18
Side effects of Radial Shock Wave Therapy (RSWT®) using the Swiss DolorClast®
When performed properly, RSWT® with the Swiss DolorClast® has only minimal risks.
Typical device-related nonserious adverse events are:
- Pain and discomfort during and after treatment (anesthesia is not necessary)
- Reddening of the skin
- Swelling and numbness of the skin over the treatment area
These device-related nonserious adverse events usually disappear within 36h after the treatment.
Accordingly the following contraindications of RSWT® using the Swiss DolorClast® must be considered:
- Treatment over air-filled tissue (lung, gut)
- Treatment of pre-ruptured tendons
- Treatment of pregnant women
- Treatment of patients under the age of 18 years (except for Osgood-Schlatter disease and muscular dysfunction in children with spastic movement disorders)
- Treatment of patients with blood-clotting disorders (including local thrombosis)
- Treatment of patients treated with oral anticoagulations
- Treatment of tissue with local tumors or local bacterial and/or viral infections
- Treatment of patients treated with cortisone